Crossmark

Reply to letters to the editor: Discordance in estrogen receptor and change of Ki67 between primary site and metastatic site of recurrent breast cancer

Crossref DOI link: https://doi.org/10.1007/s10549-020-05695-2

Published Online: 2020-05-21

Published Print: 2020-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Watanabe, Junichiro https://orcid.org/0000-0001-9226-895X
License Information

Text and Data Mining valid from 2020-05-21

Version of Record valid from 2020-05-21
More Information

Article History

Received: 9 May 2020

Accepted: 15 May 2020

First Online: 21 May 2020

Compliance with ethical standards

:

: Junichiro Watanabe has received lecture fees from Chugai Pharmaceuticals, Daiichi-Sankyo, Eisai Co. Ltd. Eli Lilly, Novartis Pharma, Pfizer and Taiho Pharmaceuticals. This study was conducted in full compliance of the laws and after obtaining approval from the institutional review board of institutions where the study was conducted.

: Informed consent was obtained from all patients included in the study.

Document is current

Any future updates will be listed below